Kinetic Analysis of 2-[C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Preliminary Patient Results
2-[ 11 C]Thymidine (TdR), a PET tracer for cellular proliferation, may be advantageous for monitoring brain tumor progression and response to therapy. Kinetic analysis of dynamic TdR images was performed to estimate the rate of thymidine transport ( K 1t ) and thymidine flux ( K TdR ) into brain tum...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2002-07-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.1162/15353500200202115 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841563178878631936 |
|---|---|
| author | Joanne M. Wells David A. Mankoff Janet F. Eary Alexander M. Spence Mark Muzi Finbarr O'Sullivan Cheryl B. Vernon Jeanne M. Link Kenneth A. Krohn |
| author_facet | Joanne M. Wells David A. Mankoff Janet F. Eary Alexander M. Spence Mark Muzi Finbarr O'Sullivan Cheryl B. Vernon Jeanne M. Link Kenneth A. Krohn |
| author_sort | Joanne M. Wells |
| collection | DOAJ |
| description | 2-[ 11 C]Thymidine (TdR), a PET tracer for cellular proliferation, may be advantageous for monitoring brain tumor progression and response to therapy. Kinetic analysis of dynamic TdR images was performed to estimate the rate of thymidine transport ( K 1t ) and thymidine flux ( K TdR ) into brain tumors and normal brain. These estimates were compared to MRI and pathologic results. Methods: Twenty patients underwent sequential [ 11 C]CO 2 (major TdR metabolite) and TdR PET studies with arterial blood sampling and metabolite analysis. The data were fitted using the five-compartment model described in the companion article. Results: Comparison of model estimates with clinical and pathologic data shows that K 1t is higher for MRI contrast enhancing tumors ( p > .001), and K TdR increases with tumor grade ( p > .02). On average, TdR retention was lower after treatment in high-grade tumors. The model was able to distinguish between increased thymidine transport due to blood–brain barrier breakdown and increased tracer retention associated with tumor cell proliferation. Conclusion: Initial analysis of model estimates of thymidine retention and transport show good agreement with the clinical and pathological features of a wide range of brain tumors. Ongoing studies will evaluate its role in measuring response to treatment and predicting outcome. |
| format | Article |
| id | doaj-art-e03d8442acd1448f9e7e5605ce3d5550 |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2002-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-e03d8442acd1448f9e7e5605ce3d55502025-01-03T00:10:43ZengSAGE PublishingMolecular Imaging1536-01212002-07-01110.1162/1535350020020211510.1162_15353500200202115Kinetic Analysis of 2-[C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Preliminary Patient ResultsJoanne M. Wells0David A. MankoffJanet F. Eary1Alexander M. Spence2Mark Muzi3Finbarr O'Sullivan4Cheryl B. Vernon5Jeanne M. Link6Kenneth A. Krohn7University of WashingtonUniversity of WashingtonUniversity of WashingtonUniversity of WashingtonUniversity College CorkUniversity of WashingtonUniversity of WashingtonUniversity of Washington2-[ 11 C]Thymidine (TdR), a PET tracer for cellular proliferation, may be advantageous for monitoring brain tumor progression and response to therapy. Kinetic analysis of dynamic TdR images was performed to estimate the rate of thymidine transport ( K 1t ) and thymidine flux ( K TdR ) into brain tumors and normal brain. These estimates were compared to MRI and pathologic results. Methods: Twenty patients underwent sequential [ 11 C]CO 2 (major TdR metabolite) and TdR PET studies with arterial blood sampling and metabolite analysis. The data were fitted using the five-compartment model described in the companion article. Results: Comparison of model estimates with clinical and pathologic data shows that K 1t is higher for MRI contrast enhancing tumors ( p > .001), and K TdR increases with tumor grade ( p > .02). On average, TdR retention was lower after treatment in high-grade tumors. The model was able to distinguish between increased thymidine transport due to blood–brain barrier breakdown and increased tracer retention associated with tumor cell proliferation. Conclusion: Initial analysis of model estimates of thymidine retention and transport show good agreement with the clinical and pathological features of a wide range of brain tumors. Ongoing studies will evaluate its role in measuring response to treatment and predicting outcome.https://doi.org/10.1162/15353500200202115 |
| spellingShingle | Joanne M. Wells David A. Mankoff Janet F. Eary Alexander M. Spence Mark Muzi Finbarr O'Sullivan Cheryl B. Vernon Jeanne M. Link Kenneth A. Krohn Kinetic Analysis of 2-[C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Preliminary Patient Results Molecular Imaging |
| title | Kinetic Analysis of 2-[C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Preliminary Patient Results |
| title_full | Kinetic Analysis of 2-[C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Preliminary Patient Results |
| title_fullStr | Kinetic Analysis of 2-[C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Preliminary Patient Results |
| title_full_unstemmed | Kinetic Analysis of 2-[C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Preliminary Patient Results |
| title_short | Kinetic Analysis of 2-[C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Preliminary Patient Results |
| title_sort | kinetic analysis of 2 c thymidine pet imaging studies of malignant brain tumors preliminary patient results |
| url | https://doi.org/10.1162/15353500200202115 |
| work_keys_str_mv | AT joannemwells kineticanalysisof2cthymidinepetimagingstudiesofmalignantbraintumorspreliminarypatientresults AT davidamankoff kineticanalysisof2cthymidinepetimagingstudiesofmalignantbraintumorspreliminarypatientresults AT janetfeary kineticanalysisof2cthymidinepetimagingstudiesofmalignantbraintumorspreliminarypatientresults AT alexandermspence kineticanalysisof2cthymidinepetimagingstudiesofmalignantbraintumorspreliminarypatientresults AT markmuzi kineticanalysisof2cthymidinepetimagingstudiesofmalignantbraintumorspreliminarypatientresults AT finbarrosullivan kineticanalysisof2cthymidinepetimagingstudiesofmalignantbraintumorspreliminarypatientresults AT cherylbvernon kineticanalysisof2cthymidinepetimagingstudiesofmalignantbraintumorspreliminarypatientresults AT jeannemlink kineticanalysisof2cthymidinepetimagingstudiesofmalignantbraintumorspreliminarypatientresults AT kennethakrohn kineticanalysisof2cthymidinepetimagingstudiesofmalignantbraintumorspreliminarypatientresults |